Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502955 | 0.85 | TSHR (0.58) | TSHRHPGDALDH1A1CYP3A4HCAR2 | |
| SCHEMBL7974868 | 0.85 | TSHR (0.59) | TSHRALDH1A1HCAR2EPHX1FAAH | |
| Methacrylic Acid SCHEMBL28214417 | 0.84 | TSHR (0.58) | TSHRHPGDALDH1A1CYP3A4HCAR2 | |
| Methacrylic Acid SCHEMBL15733333 | 0.84 | TSHR (0.58) | TSHRHPGDALDH1A1CYP3A4HCAR2 | |
| Acrylic Acid Ethyl Ester SCHEMBL9067599 | 0.84 | NPSR1 (0.38) | TSHRHPGDALDH1A1CYP3A4HCAR2 | |
| SCHEMBL8766185 | 0.84 | TSHR (0.48) | TSHRHPGDALDH1A1CYP3A4HCAR2 | |
| SCHEMBL14660709 | 0.84 | TSHR (0.60) | TSHRHPGDALDH1A1HCAR2EPHX1 | |
| SCHEMBL17063567 | 0.84 | TSHR (0.60) | TSHRHPGDALDH1A1HCAR2EPHX1 | |
| SCHEMBL6274865 | 0.84 | TSHR (0.60) | TSHRHPGDALDH1A1HCAR2EPHX1 | |
| SCHEMBL28078386 | 0.84 | TSHR (0.60) | TSHRHPGDALDH1A1HCAR2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312606-A1 | MCL-1 INHIBITOR FORMULATIONS | AMGEN INC. (US) | 2023-10-05 | — | — | US | claimed |
| EP-4203922-A1 | MCL-1 INHIBITOR FORMULATIONS | Amgen Inc. (US) | 2023-07-05 | — | — | EP | claimed |
| EP-3821882-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240217933-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240199550-A1 | SALTS AND CRYSTAL FORMS OF OMECAMTIV MECARBIL | AMGEN INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240189240-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLMITRIPTAN | MAPLIGHT THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| WO-2024076979-A1 | CELLULOSE NANOFIBER-BASED COMPOSITIONS FOR EHNANCED FILTRATION EFFICIENCY AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-3573617-B1 | PYRAZOL-BASED COMPOUNDS FOR USE IN TREATING NASH AND CIRRHOSIS | APTABIO THERAPEUTICS INC (KR) | 2024-04-03 | — | — | EP | disclosed |
| CN-117750957-A | Pharmaceutical composition comprising zolmitriptan | 地图之光治疗股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11926592-B2 | Salts and crystal forms of omecamtiv mecarbil | AMGEN INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20070184115-A1 | Modified release formulations of tramadol and uses thereof | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (CA) | 2007-08-09 | — | — | US | disclosed |
| WO-2007078895-A2 | MODIFIED RELEASE FORMULATIONS OF TRAMADOL AND USES THEREOF | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-07-12 | — | — | WO | disclosed |
| US-20060280793-A1 | Oral sustained-release preparation of fasudil hydrochloride | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-12-14 | — | — | US | disclosed |
| US-7125567-B2 | Process for producing an oral sustained-release preparation of fasudil hydrochloride | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20050106245-A1 | Sustained release preparations and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1484056-A1 | SUSTAINED RELEASE PREPARATIONS AND PROCESS FOR PRODUCING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040131679-A1 | Process for producing an oral sustained-release preparation of fasudil hydrochloride | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-07-08 | — | — | US | disclosed |
| US-6699508-B1 | SUSTAINED-RELEASE COATED PARTICLE COMPRISING A CORE COMPRISING DRUG AND A COATING COMPRISING INSOLUBLE AUXILIARY MATERIAL, THE PREPARATION EXHIBITING A SPECIFIC DISSOLUTION RATE | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-02 | — | — | US | disclosed |
| EP-1110553-A1 | SUSTAINED RELEASE ORAL PREPARATIONS OF FASUDIL HYDROCHLORIDE | Asahi Kasei Kabushiki Kaisha (JP) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199550-A1 | SALTS AND CRYSTAL FORMS OF OMECAMTIV MECARBIL | SI, MGAM, GCG | TSHR 4116/4885HPGD 3061/4885ALDH1A1 2933/4885 |
| US-20060280793-A1 | Oral sustained-release preparation of fasudil hydrochloride | MYLK, CFL1, CYP3A5 | TSHR 1906/4885HPGD 840/4885ALDH1A1 1945/4885 |
| US-20040131679-A1 | Process for producing an oral sustained-release preparation of fasudil hydrochloride | SAMM50, CYP3A5, VEGFA | TSHR 2349/4885HPGD 926/4885ALDH1A1 2211/4885 |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | VIP, PTMS, IAPP | TSHR 2949/4885HPGD 1136/4885ALDH1A1 4861/4885 |
| US-20240189240-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLMITRIPTAN | HTR3A, HTR5A, GRIN3A | TSHR 1913/4885HPGD 2218/4885ALDH1A1 3176/4885 |
| US-11926592-B2 | Salts and crystal forms of omecamtiv mecarbil | SI, MGAM, GCG | TSHR 4116/4885HPGD 3061/4885ALDH1A1 2933/4885 |
| US-20230312606-A1 | MCL-1 INHIBITOR FORMULATIONS | MCL1, BAK1, BCL2L1 | TSHR 4494/4885HPGD 2358/4885ALDH1A1 650/4885 |
| US-20240217933-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | SI, MLN, MLNR | TSHR 3530/4885HPGD 139/4885ALDH1A1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.